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Abstract 
Background: Phthalic acid esters are widely used to improve the plasticity of PVC in medical 
devices (MD). The most famous plasticizer is DEHP, whose use in medical devices has been 
contested by the European authorities since 2008. Several alternative plasticizers are being 
considered to replace DEHP, such as DEHT, TOTM, DINP or DINCH, but they are also 
released from the PVC throughout their life cycle and are metabolized in the same way as 
DEHP. 
Objectives: Our study focuses on the in vitro cytotoxicity of two alternative plasticizers 
(DINCH and DINP) contained in certain medical devices. They are likely to migrate and be 
transformed in vivo into the primary and secondary metabolites by a metabolism similar to 
that of DEHP. This preliminary study is the first to assess the in vitro cytotoxicity of oxidized 
metabolites of DINCH and DINP based on the EN ISO 10-993-5 standards documents. 
Methods: We have studied the complete multi-step organic synthesis of secondary 
metabolites of DINP and DINCH and have performed cytotoxicity tests on L929 murine cells 
according to the ISO-EN ISO 10993-5 standard design for the biocompatibility of a MD. The 
tested concentrations of obtained metabolites (0.01, 0.05 and 0.1 mg/mL) covered the range 
likely to be found for DEHP (total metabolism) in biological fluids coming into direct contact 
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with the MD. The concentrations tested in our study were chosen based on a complete 
transformation of the plasticizers released after direct contact between a MD and the 
patient's blood. 
Results 
Only 7-oxo-MMeOCH is cytotoxic at the highest concentration (0.1 mg/mL) after 7 days of 
exposure, just like 5-oxo-MEHP for the same concentration. By contrast, 7-OH-MMeOP, 7-
cx-MMeOP, 7-oxo-MMeOP, 7-OH-MMeOCH and 7-cx-MMeOCH were not found to be 
cytotoxic.  
Conclusion: The known concentrations of these secondary metabolites in urinary samples 
are in the μg/L range, i.e. about 100-1000 times lower than the concentrations tested in this 
study. Cytotoxicity is known to be dose-dependent but it is not always the case for endocrine 
perturbations and the secondary metabolites could induce endocrine perturbations at very 
low doses.  
Keywords 
DINCH, DINP, metabolite synthesis; cytotoxicity, DEHP-alternative plasticizers  
Abbreviations  
ARMED®, Assessment and Risk Management of Medical Devices in Plasticized 
Polyvinylchloride; DEHP, diethylhexyl phthalate; DINCH, diisononyl cyclohexane-1,2-
dicarboxylate; DINP, di-isononylphthalate; MEHP, monoethylhexyl phthalate; MMeOP, 
mono(4-methyloctyl)phthalate; MMeOCH, mono(4-methyloctyl) cyclohexane-1,2-
dicarboxylate; MINCH, monoisononyl cyclohexane-1,2-dicarboxylate; MINP, 
monoisononylphthalate; 7-oxo-MMeOCH, mono(4-methyl-7-oxooctyl) cyclohexane-1,2-
dicarboxylate, 7-OH-MMeOCH mono(7-hydroxy-4-methyl-octyl) cyclohexane-1,2-
dicarboxylate, 7-cx-MMeOCH, mono(7-carboxy-4-methyl-octyl) cyclohexane-1,2-
dicarboxylate, 7-oxo-MMeOP, mono(4-methyl-7-oxooctyl)phthalate, 7-OH-MMeOP mono(7-
hydroxy-4-methyloctyl)phthalate, 7-cx-MMeOP, mono(7-carboxy-4-methyloctyl)phthalate 
SCENIHR, Scientific Committee on Emerging and Newly-Identified Health Risks. 
1 INTRODUCTION 
Some phthalate esters present a general concern for public health due to their wide use in 
the manufacturing of polymeric materials and various consumer products. Some phthalate 
esters can be classified into two categories according to the number of carbons in the ester 
chain. On the one hand, there are those with a low molecular weight (number of carbon 
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inferior to 6) which are used as industrial solvents, lubricants, and as components in 
personal-care products. On the other hand, those with a high molecular weight are 
commonly used as plasticizers, conferring better flexibility and durability to everyday 
polyvinyl chloride (PVC) consumer products, such as flooring, food packaging, clothing, 
children’s toys and medical devices (Hauser and Calafat, 2005). These PVC plasticizers can 
be released from the polymers by volatilization into the air, abrasion of the polymer, leaching 
into liquids and direct diffusion from the polymer into dust on the polymer surface, resulting in 
subsequent human exposure which might cause adverse health effects (Giovanoulis G et al. 
2018; Zhang, S. et al. 2016; Engel, A. et al., 2017, 2018). With regard to their presence in 
PVC medical devices, the most famous plasticizers is DEHP, whose use has been contested 
by the European authorities (SCENHIR, 2008, 2016). The toxic potential of DEHP is largely 
due to the metabolic transformation into more toxic metabolites by hydrolysis (MEHP) and 
subsequent oxidation reactions (5-OH-MEHP, 5-oxo-MEHP, 5-cx-MEHP) (Figure 1A). 
Numerous studies have been carried out on DEHP, leading to its classification as 
carcinogenic, mutagenic and or toxic for reproduction (CMR1B) because of its toxic effects 
on reproduction and fertility in rodents. Its use is now highly controlled in medical devices. 
The European regulation 2017/745 recommends not to exceed a rate of 0.1% in mass 
fraction in each medical device (Regulation (EU) 2017/745). Two alternative plasticizers 
(diisononyl phthalate (DINP) and 1,2-cyclohexane dicarboxylic acid (DINCH)) have been 
considered by manufacturers as a replacement for DEHP in many PVC products, such as 
medical devices and food packaging, but not in toys are limited in toys with concentrations 
inferior to 0.1% by weight of the plasticized material (European Chemical Agency, 2013; 
SCENHIR, 2016), due to their physicochemical properties suggesting a lower migration and 
more favorable toxicological profile (Fromme et al 2016, Bhat et al 2014) than DEHP. DINP 
and DINCH respectively constitute a complex commercial mixture composed mainly of 
isomers of phthalate or dialkyl cyclohexanoate with 9 carbon chains. DINCH (Hexamoll®) is 
manufactured by catalytic hydrogenation of the aromatic ring of diisononyl phthalate 
(Palatinol® N) into the cyclohexane ring existing predominantly in the most stable chair 
configuration, allowing cis- and trans-configuration. The typical commercial products consist 
of 90% cis- and 10% trans-isomers. In both molecules, the 4-methyl isomer forms a fraction 
that represents less than 50% of the total C9 alcohols (Schütze et al. 2017). Like DEHP, they 
are not covalently bonded to the PVC to which they are mixed. As a result, they are released 
from the products throughout their life cycle (Bernard et al 2015; Jeon et al. 2016). Because 
they are a mixture of isomers, their metabolites are also isomeric mixtures (Silva et al. 2013). 
Both are initially hydrolyzed in rodents and humans into their monoester (MINP or MINCH), 
followed by oxidative processes into several metabolites including mono-hydroxy, mono-oxo 
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and mono-carboxymetabolites (Silva et al., 2007a, 2007b, Koch et al. 2007a, 2007b, 2013) 
(Figure 1B). 
Some biomonitoring studies carried out in humans have made it possible to demonstrate the 
presence of DINCH and DINP metabolites in biological media such as urine, blood and nails 
(Gianouvoulis et al. 2016, 2018, Correia-Sa et al. 2017, Schütze et al. 2012, 2017, Zeman et 
al. 2013; Koch et al. 2017, Johns LE 2015). However, despite the animal toxicology data and 
the in vitro toxicity of the plasticizers, there is almost no information on the in-vitro toxicity of 
the oxidized metabolites of DINP and DINCH from medical devices except the urinary 
metabolites of DINCH, which seem to have an impact on the activities of the human nuclear 
receptors ERα, ERβ, AR, PPARα and PPARγ. However, the in vitro data does not support 
the notion that DINCH or any of the investigated metabolites may exert considerable 
endocrine effects in vivo at relevant human exposure levels. (Engel et al. 2017 and 2018). In 
a previous study we investigated the cytotoxicity of DEHP, DINCH, DINP and their 
corresponding primary unconjugated metabolites (MEHP, MINCH, MMeOCH, MINP, 
respectively), and showed that the primary metabolites are more cytotoxic than their 
corresponding plasticizer at concentrations between 0.01 and 0.1 mg/mL. Only MMeOP, the 
primary metabolite of DINP, is not cytotoxic at these concentrations (Eljezi et al., 2017). 
Taking into account that DINP and DINCH are metabolized in the same way as DEHP, 
secondary metabolites are also found in the urine (7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-
MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MmeOP) in a glucuroconjugated form or 
not. According to the data in the literature, it appears that 26 % of cx-MINCH are excreted in 
its unconjugated form in urine (Koch et al., 2013). These results are similar to the previous 
work concerning DEHP and DINP (Silva et al., 2003). In continuation of our work on 
alternative plasticizers to DEHP, we therefore undertook the total synthesis of the secondary 
metabolites of DINP and DINCH in order to be able to carry out a first cytotoxicity study on 
the NCTC clone 929 in accordance with the EN ISO 10-993-5 standards documents. 
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Figure 1: Primary and secondary metabolites of DEHP, DINCH, DINP, MeDINCH and 
MeDINP 
2 MATERIALS AND METHODS 
2.1. Chemicals, biochemicals and reagents 
Unless otherwise mentioned, all manipulations were performed under an argon atmosphere. 
All reagents were purchased from the following commercial suppliers: Sigma-Aldrich, Acros 
Organics, Carlo Erba, TCI Europa, and Alpha Aesar. Anhydrous DMF and anhydrous 
triethylamine were purchased from Acros Organics. THF was distilled over benzophenone 
and sodium. Dichloromethane was distilled over calcium hydride. Nuclear magnetic 
resonance (NMR) spectra were acquired on a Bruker AC-200 or AC-400 instrument 
operating at 200 MHz and 50 MHz or 400 MHz and 100 MHz for 1H NMR and 13C NMR, 
respectively. All 1H NMR and 13C NMR spectral peaks are reported in δ units, parts per 
million (ppm), and the coupling constants are indicated in hertz (Hz). The following 
abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quadruplet, 
m = multiplet, and br = broad. The chromatographic system consisted of an HTC PAL 
autosampler, and a Transcend TLX-1 HTLC System (ThermoFisher Scientific, San Jose, 
United States). The HRMS analysis was performed using a Thermo Exactive benchtop 
Orbitrap® instrument. TLC was performed on pre-coated silica gel sheets (POLYGRAM® 
60F254 plates) and visualized under UV light (254 nm). Revelators used were KMnO4 (1.5 g 
KMnO4, 10 g K2CO3, and 1.25 mL 10% NaOH in 200 mL water) and ninhydrin (1.5 g 
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ninhydrin in 100 mL of n-butanol with 3 mL AcOH). Column chromatography was performed 
using a silica gel normal phase (35–70 μm). A HPLC Prominence-i LC-2030 CSCHIMADZU 
with Kinetex 5 µm EVO C18 (Phenomenex) column with pore diameter (A) 82-102, particle 
size (µm) 4.5-4.8, and column dimensions of 50 x 4.6 mm was used to purify secondary 
metabolites. Uncorrected melting points (Mp) were recorded on an Electrothermal IA9300 
apparatus. Infrared spectra (IR) were recorded on a Bruker FT Vector 22. The 5-oxo-MEHP, 
5-OH-MEHP and 5-cx-MEHP compounds were synthesized using the procedure described 
by Nüti et al. (Nüti et al, 2005).  
Dimethylsulfoxide DMSO (ref: D8418 CAS: 67-68-5), Mouse fibroblasts L929 (ref: 85011425 
lot: 10L019), MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, ref: 
M2128) were also purchased from Sigma Aldrich. Dulbecco’s modified Eagle Medium 
(DMEM) (fetal calf serum (SVF), phosphate saline buffer (PBS), penicillin (P), streptomycin 
(S), and actinomycin D) were purchased from Life technologies SAS, France. For more 
details, see supporting information. 
2.2. Methods for the synthesis of the secondary metabolites 7-oxo-MMeOCH, 7-OH-
MMeOCH, 7-cx-MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP 
 
Metabolites 7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-MMeOCH, 7-oxo-MMeOP, 7-OH-
MMeOP and 7-cx-MMeOP were synthesized from the appropriate anhydrides 
(hexahydroisobenzofuran-1,3-dione or phtalic anhydride) and 7-(benzyloxy)-4-methylheptan-
1-ol previously synthesized and characterized (1H, 13C NMR and HRMS) by our lab (Eljezi et 
al. 2017). The benzyl group at -position was then removed under hydrogen atmosphere 
and the resulting alcohol was oxidized into an aldehyde compound which was converted into 
vinyl compounds 6 or 18. From the appropriate vinyl compound (6 or 18), 7-oxo-MMeOCH or 
7-oxo-MMeOP could be obtained by oxidation in a mixture of PdCl2 and parabenzoquinone. 
These were directly converted into 7-OH-MMeOCH or 7-OH-MMeOP by a regioselective 
reduction in the presence of NaBH4. Concerning 7-cx-MMeOCH or 7-cx-MMeOP, they were 
obtained from vinyl derivatives 6 or 18 by hydroboration followed by an oxidation in the 
presence of Jones reagent. The purity of all synthesized metabolites was over 95% 
(HPLC/MS). All experimental details are described in the supporting material. 
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2.3. Biocompatibility assays 
For the solubilization of the plasticizers, cell cultures, viability assays for the synthesized 
metabolites and statistical analysis, we used the same procedures previously described by 
us (Eljezi et al. 2017). For more details, see supporting information. 
3 RESULTS 
Synthesis of MeDINCH and MeDINP secondary metabolites 
The three metabolites of the MeDINCH plasticizer, i.e. 7-oxo-MMeOCH, 7-OH-MMeOCH 
and 7-cx-MMeOCH, were synthesized from monoprotected alcohol 1 (Eljezi et al.2017) and 
hexahydroisobenzofuran-1,3-dione (Scheme 1). Acid compound 2 was esterified, followed by 
a catalytic hydrogenation to produce compound 4. The hydroxy group at -position of the 
alkyl chain was oxidized into an aldehyde. Compound 5 reacted with 
isopropyltriphenylphosphonium iodide (Wittig reaction) to obtain vinyl derivative 6. According 
to the procedure previously described (Nüti et al. 2005), this vinyl function produced a ketone 
function at position C-7 of the alkyl chain (compound 7) which was converted into 7-oxo-
MMeOCH after a soft saponification. Compound 7 was also reduced in the presence of 
NaBH4 followed by a treatment with lithium hydroxide monohydrate to give 7-OH-MMeOCH. 
Finally, the third secondary metabolite, 7-cx-MMeOCH, was obtained from compound 6 after 
a hydroboration of the vinyl function, followed by an oxidation of the primary alcohol function 
with Jones reagent and a soft saponification. All of these syntheses are depicted in Scheme 
1.  
Scheme 1. Synthesis of secondary metabolites 7-oxo-MMeOCH, 7-OH-MMeOCH and 7-
cx-MMeOCH  
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The secondary metabolites 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP were 
synthesized using a similar strategy developed for secondary metabolites of MeDINCH 
(Scheme 2). Briefly, vinylic precursor 18 was obtained by condensation of the monoprotected 
alcohol 1, and anhydride phthalic, followed by an esterification, deprotection of the -hydroxy 
group at C-7 position, then its oxidation and a Wittig reaction. Finally, this vinyl function 
enabled 7-oxo-MMeOP to be obtained in two steps (Wacker oxidation and a soft 
saponification), then 7-OH-MMeOP by a reduction in presence of NaBH4. Compound 7-cx-
MMeOP was obtained after a hydroboration, followed by an oxidation with Jones reagent.  
Scheme 2. Synthesis of secondary metabolites 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-
MMeOP.  
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3.2. Viability of cells when exposed to the secondary metabolites of plasticizers 
Figure 2 shows the results of viability tests, at day 7 (D7), performed on L929 cells cultured 
in the presence of the three concentrations of plasticizers after 7 days of contact. 
Compounds 5-cx-MEHP, 5-OH-MEHP, 7-cx-MMeOCH, 7-OH- MMeOCH, 7-cx-MMeOP, 7-
OH-MMeOP, 7-oxo-MMeOP were not toxic to the cells at concentrations of 0.01, 0.05, and 
0.1 mg/mL compared with the control containing DMSO at the same concentrations. A 
decrease in cell viability was observed for 5-oxo-MEHP and 7-oxo-MMeOCH from the 
concentration of 0.1 mg/mL. A significant decrease in viability of over 50% was observed for 
5-oxo-MEHP 
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Figure 2: Cytotoxicity tests of secondary metabolites at 0.01 mg/mL, 0.05 mg/mL and 0.1 mg/mL, on 
day 7. Outcomes of the cell viability analysis using a MTT assay. L929 cells were seeded at 104 
cells/well and cultured for 7 days in three conditions: control (complete medium), control DMSO 
(complete medium supplemented with 0.1%, 0.5% and 1% DMSO) and test (working solutions of the 
plasticizer in complete medium at 0.01 mg/mL, 0.05 mg/mL and 0.1 mg/mL). MTT assays and 
quantification of the viability percentage were carried out every day. *p < 0.05 DMSO control vs Test. 
 
4. DISCUSSION 
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For several years, our research program has focused on DEHP and some of the 
corresponding alternatives in medical devices. DINCH and DINP are two plasticizers 
commonly used as alternatives to DEHP in PVC medical devices. DINCH is used in 
parenteral and enteral nutrition tubings as well as in hemodialysis lines (Strommen et al. 
2016). DINP is added to some PVC infusions tubings or blood transfusion sets (Fredericks et 
al. 2014; Bernard et al. 2015; Bourdeaux et al. 2016). Like DEHP, these plasticizers are also 
known to migrate from medical devices and to enter into contact with the patient's body 
where they are metabolized into primary and secondary forms (Bernard et al. 2015). Based 
on data obtained from ICU studies carried out in recent years (Fredericksen Frederiksen et 
al. 2014; Huygh et al. 2015; Strommen et al. 2016), it seems that these metabolites are less 
present in the urine than those of DEHP. Although these metabolites are mainly eliminated in 
their conjugated form in the urine, about 26% of the acid form is in its free form (5cx-MINCH) 
(Koch et al., 2013). Similar data have been published for DEHP and DINP (Silva et al., 
2003). The cytotoxicity of their respective primary metabolites (MINCH, MeMINCH, MINP 
and MeMINP) has also been evaluated (Eljezi et al. 2017) but the cytotoxicity of the 
secondary metabolites of DINCH and DINP have not currently been studied. We thus 
synthesized these secondary metabolites (7-oxo-MMeOCH, 7-OH-MMeOCH, 7-cx-
MMeOCH, 7-oxo-MMeOP, 7-OH-MMeOP and 7-cx-MMeOP) in sufficient quantities to 
complete preliminary cytotoxicity test. Based on the urinary concentrations found for these 
secondary metabolites (conjugates or not), the concentrations of the secondary metabolites 
of DEHP are much higher than those of DINP and DINCH (0.3-5 µg/mL for DEHPm versus 
0.008-0.1 µg/mL for DINPm and DINCHm) (Frederiksen et al., 2014; Huygh et al., 2015; 
Strommen et al., 2016). We therefore evaluated the cytotoxicity of the secondary metabolites 
of DINP and DINCH over a larger concentration range (0.01-1 mg/mL), which is a very 
pessimistic scenario, and compared these results with those obtained for the secondary 
metabolites of DEHP. We chose this concentration range in order to take into account the 
fact that DINCH and DINP could be increasingly used in the composition of medical devices, 
thus exposure to them is expected to increase in the coming years. It must also be taken into 
consideration that patients in intensive care units are exposed to several medical devices 
that may contain these alternative plasticizers (Huygh et al. 2015; Strommen et al. 2016). 
Metabolites 7-OH-MMeOP, 7-OH-MMeOCH, 7-cx-MMeOP, 7-cx-MMeOCH do not cause 
any cytotoxicity up to concentrations of 0.1 mg/mL, just like the corresponding secondary 
metabolites of DEHP, i.e. 7-OH-MEHP and 5-cx-MEHP. This is also true for 7-oxo-MMeOP, 
the third secondary metabolite of DINP. However, 7-oxo-MMeOCH, like 5-oxo-MEHP, has 
been shown to be cytotoxic at 0.1 mg/mL. No cytototoxicity was observed at a concentration 
below 0.05 mg/mL. The concentrations tested in our study were chosen on the basis of a 
complete transformation of the plasticizers released after direct contact between a MD and 
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the patient's blood (SCENHIR 2015 2016, Eckert E et al., 2015, 2016). However, the 
secondary metabolites, derived from the hepatic metabolism of the primary metabolite of the 
plasticizer (itself derived from an enzymatic hydrolysis of the plasticizer) are present at much 
lower concentrations in body fluids. Human biomonitoring studies (Schütze et al. 2014, Koch 
et al. 2007a, 2007b) performed after the introduction of DINCH and DINP on to the market 
show that the concentrations of their secondary metabolites in urinary samples are in the 
μg/L range (example 0.71 μg/L for 7-OH-MMeOCH, 0.33 μg/L for 7-oxo-MMeOCH, 0.61 μg/L 
for 7-cx-MMeOCH, 14.9 μg/L for 7-OH -MMeOP, 8.9 μg/L for 7-oxo-MMeOP and 16.4 μg/L 
for 7-cx-MMeOP), which is about 100-1000 times lower than the concentrations tested. The 
DEHP secondary metabolites found in the urine of humans exposed for two decades are 
also in the order of μg/L (21.0 μg/L for 5-OH-MEHP, 16.7 μg/L for 5-oxo-MEHP, 26,9 μg/L for 
5-cx-MEHP) (Wittassek et al. 2007). Therefore, we can consider that these secondary 
metabolites of DINCH and DINP do not present a risk of cytotoxicity at the doses found in the 
body. This information, combined with the toxicity data obtained in animals, is reassuring with 
regard to the use of MDs plasticized with DINCH or DINP for situations where there is no 
direct contact with the patient’s biological fluids (infusers, extension lines, nutrition tubings). 
In the case of a direct contact between the plasticized PVC in medical device and the 
patient's blood (extracorporeal circulation in cardiac surgery, dialysis), the risk could be 
different. In our previous study, we showed the cytotoxicity of primary metabolites of DINP 
and DINCH at 0.05 mg/mL (Eljezi et al. 2017). During an extracorporeal circulation, the 
plasticizer released from the MD (extracorporeal circulation line) is hydrolyzed into its 
glucuroconjugated primary metabolite. However, studies on plasticized DINCH blood bags 
have shown that this does not affect plasma quality and the amount of DINCH released is 
less pronounced than that of DEHP (Lagerberg et al. 2015). These results seem to be in 
agreement with those obtained in rats after i.v. injection or infusion of DINCH for which no 
apparent systemic effect had been observed up to 300 mg/kg bw/day (David et al. 2015). 
It should be noted that these preliminary results attempt to show that the secondary 
metabolites of DINCH and DINP do not exhibit cytotoxicity according to EN ISO 10-993-5 
standards documents. We will consider these different aspects when our biomonitoring study 
on alternative plasticizers and their corresponding metabolites are complete within the 
framework of ARMED® and ARMED-NEO projects. We will then select the different 
compounds for complementary studies. 
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Highlights 
 
 7-oxo-MMeOCH and 5-oxo-MEHP induced no action on cell proliferation at 0.1 mg/mL  
 Among secondary metabolites of DEHP, 5-oxo-MEHP induced an action on L929 
 Among secondary metabolites of MMeOCH, 7-oxo-MMeOCH induced an action on L929 
 Secondary metabolites of MMeOCH are less toxic than MMeOCH 
 Secondary metabolites of MMeOP are not toxic like MMeOCH 
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